Daily Stock List
SNAP Interactive, Inc. (STVI)
Greenbackers, TopPennyStockMovers, SmarTrend Newsletters, FeedBlitz, and SmallCapVoice reported previously on SNAP Interactive, Inc. (STVI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Incorporated on July 19, 2005, SNAP Interactive, Inc. develops, owns and operates dating applications for social networking websites and mobile platforms. The Company provides online dating applications under the Are You Interested? (AYI) and The Grade brands in the United States. SNAP Interactive is based in New York City. The Company lists on the OTC Bulletin Board.
SNAP Interactive's flagship brand is AYI.com. This is a multi-platform online dating site with a huge user database of approximately 30 million users. AYI.com‘s objective is to improve the online dating experience of meeting new people through integrating a user’s friends and interests to empower more meaningful connections. The AYI brand is fully integrated across Facebook, iPhone, Android, and the Worldwide Web. AYI is one of the first dating apps to integrate with Facebook.
Furthermore, SNAP’s The Grade is a patent-pending mobile dating application catering to high-quality singles. The Grade holds users accountable for their behavior through employing a proprietary algorithm. This algorithm assigns letter grades to users ranging from "A+" to "F" based on profile quality, responsiveness, as well as peer-reviews generated from the opinions received from other users. Users with a grade of "D" or "F" receive a warning and also instructions on how to improve their grade. Users who maintain an "F" grade are expelled.
This week, Snap Interactive announced a rebranding of AYI, its flagship dating platform. Since its beginning in 2007, AYI has built a community of singles globally, and is now rebranding as FirstMet to reflect SNAP Interactive’s vision for making it easier for single adults to meet new people in a friendly, low-pressure environment.
Mr. Alex Harrington, SNAP Interactive’s Chief Executive Officer, said, "AYI has always been a successful dating solution, offering a great way for a community of 30 million singles to meet and explore romantic relationships. However, we needed a stronger brand identity to communicate those benefits effectively to new and existing users. We are excited to unveil FirstMet, which captures the essence of our brand promise: to make it easy for single adults 35 and older to meet more people and lead happier, more fulfilling lives."
Snap Interactive will hold a conference call at 4:30 p.m. ET on Monday, March 14, 2016 to discuss its Q4 and full year 2015 financial results.
SNAP Interactive, Inc. (STVI), closed Thursday's trading session at $0.12, up 31.15%, on 8,000 volume with 3 trades. The average volume for the last 60 days is 23,492 and the stock's 52-week low/high is $0.02/$0.251
Accelerize, Inc. (ACLZ)
StockOodles, Greenbackers, and FeedBlitz reported on Accelerize, Inc. (ACLZ), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2001, Accelerize, Inc. provides marketing technology solutions that transform the way advertisers take advantage of their digital advertising data. CAKE is a division of Accelerize and is the Company’s digital marketing software division. CAKE provides a cloud-based solution to track and analyze the performance of digital marketing Return on Investment (ROI), in real-time. Listed on the OTCBB, Accelerize is headquartered in Newport Beach, California. The Company formerly went by the name Accelerize New Media, Inc. It changed its corporate name to Accelerize, Inc. in October 2014.
The Company’s CAKE is a software-as-a-service (SaaS) enterprise platform. It provides online tracking, reporting, lead distribution, as well as analytics solutions for advertisers, online marketers, affiliate marketers, and lead generators. With CAKE, one can track and optimize affiliate traffic. A user can also collect, validate and distribute leads. In addition, one can gather and analyze multi-channel data.
Accelerize offers CAKE for Advertisers and CAKE for Networks. CAKE for Advertisers is a SaaS solution. It enables brand advertisers to unify the tracking, attribution, and optimization of digital marketing spend across search, display, email, video, social, affiliate, and other marketing channels. CAKE for Networks is a marketing solution for affiliate networks. CAKE by Accelerize is based in Newport Beach, with operations in New York, London, India, and Sydney, Australia.
Last month, Accelerize and its digital marketing software division CAKE announced that BravAds chose CAKE's SaaS solution to track and analyze digital marketing campaigns across multiple channels. These include search, display and affiliate. BravAds is a performance marketing and branding agency.
This month, Accelerize and CAKE announced that Shoogloo Media implemented CAKE's SaaS solution to power its new global performance marketing network. Shoogloo Media is a performance marketing company. Launched in 2015, Shoogloo's online affiliate marketing program provides a combination of strategy, technology and execution services for engaging with new and existing customers.
With CAKE, the Shoogloo online affiliate marketplace provides high-converting offers, complete reporting, and an effective way to mange an increasing network of advertisers, publishers, agencies and developers to support its clients' digital marketing strategies.
Accelerize, Inc. (ACLZ), closed Thursday's trading session at $0.45, up 60.71%, on 507,493 volume with 77 trades. The average volume for the last 60 days is 21,806 and the stock's 52-week low/high is $0.28/$1.99.
Timberline Resources Corp. (TLRS)
Gold Investment Letter reported recently on Timberline Resources Corp. (TLRS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Timberline Resources Corp. is a gold exploration and development company listed on the OTC Markets Group’s OTCQB. The Company’s focus is Nevada. Its flagship Talapoosa Project is a partially permitted, open-pit, heap leach gold project with low capital and operating costs and strong economics at $1,150/oz Au. Timberline Resources is headquartered in Coeur d’Alene, Idaho.
Timberline Resources entered into a transaction with Gunpoint Exploration Ltd. on March 17, 2015. Timberline acquired the option to purchase 100 percent of the Talapoosa project, situated in Lyon County, Nevada. The Talapoosa property is a low-sulphidation gold/silver property in the Walker Lane gold trend of western Nevada, around 45 kilometers east of Reno.
Talapoosa highlights include an NI 43-101 resource consisting of 1,012,802 oz gold (M&I); 233,532 oz gold (Inferred). Highlights also include near-surface oxide gold ounces totaling 162,581 oz (M&I); 47,745 oz (Inferred). Talapoosa has well-established infrastructure.
In addition, Timberline Resources’ exploration efforts have been focused at the Company’s 23 square-mile Eureka land package. This is one of the largest remaining undeveloped gold properties in Nevada. Timberline Resources acquired the Eureka property, including Lookout Mountain, in its 2010 acquisition of Staccato Gold.
Eureka is on the south end of Nevada’s Battle Mountain/Eureka Trend. It is four miles from Barrick Gold’s five-million ounce Archimedes/Ruby Hill mine. Eureka includes Timberline Resources’ above-mentioned Lookout Mountain project and a pipeline of earlier-stage projects, which feature past gold production, historic gold estimates, and/or drill-indicated gold mineralization.
Moreover, Timberline Resources purchased a large block of patented and unpatented mining claims in June of 2012. These consist of essentially the entire Seven Troughs gold mining district near Lovelock in Pershing County, Nevada. The purchased property package encompasses 4,100 acres, comprising 64 patented and 238 unpatented lode mining claims, all of which are under a long-term lease agreement, along with 162 additional unpatented lode mining claims.
Timberline Resources Corp. (TLRS), closed Thursday's trading session at $0.1494, up 24.29%, on 6,758 volume with 8 trades. The average volume for the last 60 days is 16,639 and the stock's 52-week low/high is $0.0812/$0.78.
BioMark Diagnostics, Inc. (BMKDF)
Stock News Now and equities Canada reported earlier on BioMark Diagnostics, Inc. (BMKDF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
BioMark Diagnostics, Inc. is developing proprietary, non-invasive, and accurate cancer diagnostic solutions. These solutions can help detect, monitor and assess treatment for cancer early and cost effectively. In addition, the technology can be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. Incorporated in 2014, BioMark Diagnostics is headquartered in Richmond, British Columbia.
The Company’s corporate mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers. In essence, BioMark is an oncology focused company with advanced stage diagnostic technologies and a promising anti-body based cancer treatment pipeline. The diagnostic technology was first licensed from the University of Manitoba.
Key market applications of BioMark Diagnostics’ technology include response to treatment – Companion Diagnostics (CDx); monitoring for cancer survivors; screening tool for pan cancer; and complementing other high cost, non-specific screening technologies.
The Company’s metabolomics-based diagnostic assay permits early cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients before measurement by way of LC MS in body fluids. This acetylation is performed by the enzyme, Spermine/Spermidine N-Acetyl Transferase (SSAT).
It has been documented that elevated levels of SSAT are observed in numerous cancers. These include lung, breast, prostate, melanoma and also GI cancers. Clinical trials on cancer and healthy subjects provided proof of principle. Furthermore, analysis of SSAT mRNA levels in tissue samples permits determination of cancer kind.
Last month, BioMark Diagnostics announced progress towards Data Analysis. The Company announced that it completed the internal standards for its assay to meet both Health Canada and Food and Drug Administration (FDA) requirements for the 200 patient trial completed in the Fall of 2015.
Yesterday, BioMark Diagnostics announced a non-brokered Private Placement for up to 4,000,000 Units at a price of $0.15 per Unit to raise gross proceeds of up to $600,000. The proceeds of the private placement will be used for the continuation of BioMark Diagnostics’ Phase 3 clinical trials, marketing initiatives, as well as general working capital.
BioMark Diagnostics, Inc. (BMKDF), closed Thursday's trading session at $0.055, up 10.00%, on 309,134 volume with 13 trades. The average volume for the last 60 days is 5,813 and the stock's 52-week low/high is $0.04/$0.345.
Vericel Corp. (VCEL)
PennyStockScholar, OTCtipReporter, Profitable Trader Authority, and Zacks reported on Vericel Corp. (VCEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Vericel Corp. is a foremost developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions. The Company’s dedication is to helping people with severe diseases and conditions realize the promise of patient-specific, expanded cellular therapies. This therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition. Vericel is headquartered in Cambridge, Massachusetts and the Company lists on the Nasdaq Capital Market (NasdaqCM).
Vericel markets two autologous cell therapy products in the United States. One is Carticel® (autologous cultured chondrocytes). This is an autologous chondrocyte implant for the treatment of cartilage defects in the knee. The second is Epicel® (cultured epidermal autografts). This is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns consisting of more than or equal to 30 percent of total body surface area.
In addition, the Company is developing MACI™. This is a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee. Vericel is also developing ixmyelocel-T. This is a patient-specific multicellular therapy for the treatment of advanced heart failure owing to ischemic dilated cardiomyopathy.
Today, Vericel announced top-line results from its Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T in patients with advanced heart failure owing to ischemic dilated cardiomyopathy (DCM). The trial met its primary endpoint of demonstrating a decrease in the total number of deaths, cardiovascular hospitalizations or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment with ixmyelocel-T versus placebo.
All clinical events in the primary and secondary endpoints were adjudicated in a blinded manner by an independent adjudication committee. The incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to patients in the placebo group. Ixmyelocel-T has been granted orphan product designation by the U.S. Food and Drug Administration (FDA) for use in the treatment of DCM.
Vericel Corp. (VCEL), closed Thursday's trading session at $3.95, up 86.32%, on 29,840,636 volume with 87,987 trades. The average volume for the last 60 days is 46,786 and the stock's 52-week low/high is $1.69/$4.346.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $3.65, off by 7.83%, on 31,986 volume with 71 trades. The stock’s average daily volume over the past 60 days is 9,228, and its 52-week low/high is $1.25/$11.625.
International Stem Cell Corp. announced today it has entered into definitive agreements with two institutional healthcare investors and management for the private placement of $6.3 million of the Company's convertible preferred stock and common stock purchase warrants to purchase up to an additional $25.7 million of the Company's common stock. The gross proceeds for the initial purchase of securities consisted of $2.5 million in cash and conversion of $3.8 million debt. Dr. Andrey Semechkin, the Company's Co-Chairman and Chief Executive Officer, purchased $4.3 million of the preferred stock (on the same terms as the outside investor) through conversion of the $3.8 million of indebtedness owed to him and $500,000 of cash. The closing of the offering is expected to occur on or about March 15, 2016, subject to satisfaction of customary closing conditions set forth in the Purchase Agreement.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Nutra Pharma Corp. (NPHC)
The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0199, up 10.56%, on 434,857 volume with 18 trades. The stock’s average daily volume over the past 60 days is 458,934, and its 52-week low/high is $0.0025/$0.27.
Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.
Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer
Nutra Pharma Corp. Company Blog
Nutra Pharma Corp. News:
Nutra Pharma to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
Nutra Pharma Announces Management Expansion and Business Updates
Nutra Pharma Corp.ís (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck
Torchlight Energy Resources, Inc. (TRCH)
The QualityStocks Daily Newsletter would like to spotlight Torchlight Energy Resources, Inc. (NASDAQ:TRCH). Today, Torchlight Energy Resources, Inc. closed trading at $0.6135, up 8.93%, on 85,868 volume with 89 trades. The stock’s average daily volume over the past 60 days is 108,102, and its 52-week low/high is $0.2201/$2.44.
Torchlight Energy Resources, Inc. (NASDAQ:TRCH) is a high growth oil and gas Exploration and Production (E&P) company primarily focused on the acquisition and development of highly profitable domestic oil fields. Leveraging a diverse portfolio, carefully selected interests, and a strong management team are pillars of Torchlight's broader success strategy.
The company maintains a diversified energy portfolio by holding interests in numerous projects in multiple established plays, and currently holds interests in Texas, Oklahoma and Kansas, where its targets are established plays such as the Wolf Penn, Eagle Ford Shale, Mississippi Limestone and Hunton Limestone trends.
Torchlight is currently moving forward on the next phase of drilling on three new wells in its Orogrande Project in West Texas, where the company owns a 47.5% working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November.
The Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations, is surrounded on all four sides by leading Eagle Ford producers. Torchlight's Johnson #4 well was recently re-entered and drilled laterally to approximately 2500 feet in the Austin Chalk Formation. With more than 20 additional drilling locations on its Marcelina Creek Asset, the project has the potential to positively impact cash flows and production sustainability.
Torchlight's executive team and board of directors are led by CEO John Brda and COO Willard McAndrew III. Combined they have over 50 years of experience in the oil and gas industry as executives, investors and consultants to the industry. Their knowledge base includes all aspects of the business including: operations, mid stream, capital formation, purchase and sale of assets, re-entries, investor relations and oil and gas consulting for public and private companies. Disclaimer
Torchlight Energy Resources, Inc. Company Blog
Torchlight Energy Resources, Inc. News:
Torchlight Energy Provides Update on the Orogrande Project
Year-End Review 2015: Torchlight Energy (NASDAQ: TRCH) by StockNewsNow
Torchlight Energy Announces Success on Its Johnson #4 Re-Entry
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.645, up 4.88%, on 23,450 volume with 25 trades. The stock’s average daily volume over the past 60 days is 24,571, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Commercial Introduction of Lithium-ion Motorcycle Batteries at 75th Annual Daytona Beach Bikefest
Orlando PGA Merchandise Show Huge Success For Oakridge
Oakridge Appointment of Leading International Battery Consultants to Ensure the Company Maintains its Technological Leadership
Star Mountain Resources, Inc. (SMRS)
The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $0.55, up 0.92%, on 16,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 8,568, and its 52-week low/high is $0.35/$1.40.
Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.
Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.
The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.
Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer
Star Mountain Resources, Inc. Company Blog
Star Mountain Resources, Inc. News:
Star Mountain Resources Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
Star Mountain Resources, Inc. Closes Acquisition of Balmat Zinc Mine in New York State
Star Mountain Resources, Inc. to Acquire Balmat Zinc Mine in New York State
Today's Top 3
Top Pros' Top Picks
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Agora Holdings, Inc. (AGHI) Geegle Media Unveils Optimized FRAME for Business Use
- Alternet Systems (ALYI) Announces Caprock Research Report with Near Term Price Target of $0.05 and 'Accumulate' Recommendation
- Cherubim Interests, Inc. (CHIT) Signs MOU to Acquire Revenue-Producing Company
- Dominovas Energy Corp. (DNRG) Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala
- FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite
- Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
- GTX Corp. (GTXO) Granted New Communication Protocol Patent Under Family Tree Patent 286
- Immune Therapeutics, Inc. (IMUN) Appoints Two New Board Members
- International Stem Cell Corp. (ISCO) to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
- Lingo Media Corp. (LMDCF) Selected to the 2016 TSX Venture 50 & Ranked #1 In the Diversified Industries Sector
- Moxian, Inc. (MOXC) Enters Into Exclusive Agreement and Development Partnership With Xinhua Media Affiliate
- Nutra Pharma Corp. (NPHC) to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
- Oakridge Global Energy Solutions, Inc. (OGES) Commercial Introduction of Lithium-ion Motorcycle Batteries at 75th Annual Daytona Beach Bikefest
- OurPet's Company (OPCO) Unveils New Innovative Products at Global Pet Expo 2016
- Star Mountain Resources Inc. (SMRS) Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
- Torchlight Energy Resources, Inc. (TRCH) Provides Update on the Orogrande Project
- View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.